Table 5

Different variables associated with occurrence of hyperuricaemia

		Hyperuricaemia at the end of treatment		P value
		No	Yes
		N=107 (83.5%)	N=21 (16.5%)
Age	Range	33–69	40–66	0.230
Age	Mean±SD	51.2±7.9	53.5±8.8	0.230
Sex	Male	56 (52.3%)	17 (81%)	0.015*
Sex	Female	51 (47.7%)	4 (19%)	0.015*
BMI	Range	23–33	30–36	<0.001*
BMI	Mean±SD	29±2.1	33.7±1.4	<0.001*
Residence	Rural	52 (48.6%)	13 (61.9%)	0.265
Residence	Urban	55 (51.4%)	8 (38.1%)	0.265
Comorbidity	No	81 (75.7%)	2 (9.5%)	<0.001*
Comorbidity	Yes	26 (24.3%)	19 (90.5%)	<0.001*
Comorbidity	HTN	7 (6.5%)	1 (4.8%)	<0.001*
	DM	14 (13.1%)	4 (19%)
	HTN and DM	4 (3.7%)	6 (28.6%)
	Gout	1 (0.9%)	8 (38.1%)
	Free	81 (75.7%)	2 (9.5%)
Uric acid before ttt	Range	3–7	5–7.5	<0.001*
Uric acid before ttt	Mean±SD	4.4±0.9	6.5±0.6	<0.001*
Creatinine before ttt	Median	0.9	1.3	<0.001*
Creatinine before ttt	IQR	0.8–1	1.1–1.4	<0.001*
Creatinine end of ttt	Median	1	1.4	<0.001*
Creatinine end of ttt	IQR	0.9–1	1.4–1.9	<0.001*
Bilirubin	Range	0.7–2.2	0.7–1.5	0.076
Bilirubin	Mean±SD	1.2±0.3	1.1±0.2	0.076
Albumin	Range	3.1–4.6	3.2–4.5	0.804
Albumin	Mean±SD	3.7±0.4	3.7±0.3	0.804
INR	Range	1–1.8	1–1.6	0.571
INR	Mean±SD	1.3±0.2	1.2±0.2	0.571
Response	SVR	101 (94.4%)	21 (100%)	0.598
Response	Relapse	6 (5.6%)	0 (0%)	0.598
Treatment	SOF LED	42 (39.3%)	9 (42.9%)	0.758
Treatment	SOF DACLA	65 (60.7%)	12 (57.1%)	0.758

Independent samples t-test for parametric quantitative data between the two groups.
Mann Whitney test for non-parametric quantitative data between the two groups.
*Significant level at bold and italics p value <0.05.
BMI, body mass index; DACLA, daclatsvir; DM, diabetes mellitus; HTN, hypertension; INR, international normalised ratio; LED, ledipasvir; SOF, sofosbuvir; SVR, sustained virological response; ttt, treatment.